- Previous Close
63.00 - Open
62.90 - Bid 62.00 x --
- Ask 64.00 x --
- Day's Range
62.35 - 62.90 - 52 Week Range
60.00 - 135.00 - Volume
2,146 - Avg. Volume
55,484 - Market Cap (intraday)
42.607M - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
62.88 - EPS (TTM)
0.01 - Earnings Date Nov 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 23, 2021
- 1y Target Est
159.62
ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.
www.ecoanimalhealthgroupplc.com227
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: EAH.L
View MorePerformance Overview: EAH.L
Trailing total returns as of 2/11/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EAH.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EAH.L
View MoreValuation Measures
Market Cap
42.69M
Enterprise Value
28.04M
Trailing P/E
66.32
Forward P/E
44.44
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
0.52
Enterprise Value/Revenue
0.33
Enterprise Value/EBITDA
4.63
Financial Highlights
Profitability and Income Statement
Profit Margin
1.17%
Return on Assets (ttm)
2.14%
Return on Equity (ttm)
2.13%
Revenue (ttm)
89.42M
Net Income Avi to Common (ttm)
1.05M
Diluted EPS (ttm)
0.01
Balance Sheet and Cash Flow
Total Cash (mrq)
22.37M
Total Debt/Equity (mrq)
4.31%
Levered Free Cash Flow (ttm)
4.49M